Nigerian HIV/AIDS drug trial delay
Nigeria's planned HIV/AIDS drug trial using generic antiretrovirals,which was due to start on December 10, has now been postponed a second time because of what the Health Ministry says are organizational reasons.
The antiretrovirals to be used in the trial, which is likely to involve 10,000 adults and 5,000 children, have been delivered by the Indian producers, Ranbaxy and Cipla (Marketletters May 7 & 14), but the delays are slowing their distribution to the 18 health centers which will be running the trial. However, a Ministry official said that he hoped some patients could begin treatment before Christmas, reports the Associated Press.
The trial was first delayed in September to allow time for regulation and import procedures. Patients taking part are expected to pay less than half the $350 annual cost of the drugs which the government will pay.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze